HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge. However, the site of antibody interception of virus and the mechanism of antibody-mediated protection remain unclear. We administered a fully protective dose of the bNAb PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3. In PGT121-treated animals, we detected low levels of viral RNA and viral DNA in distal tissues for seven days following challenge. Viral RNA-positive tissues showed transcriptomic changes indicative of innate immune activation, and cells from these tissues initiated infection after adoptive transfer into naive hosts. These data demonstrate that bNAb-media...
Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important i...
Although live-attenuated human immunodeficiency virus-1 (HIV) vaccines may never be used clinically,...
AbstractImmune correlates of vaccine protection from HIV-1 infection would provide important milesto...
Non-human primates (NHPs) are the only animal model that are used to evaluate the protection efficac...
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across muc...
Improved vaccine-mediated protection against HIV-1 requires a thorough understanding of the mode of ...
Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but impor...
Improved vaccine-mediated protection against HIV-1 requires a thorough understanding of the mode of ...
ObjectivePassive administration of broadly neutralizing antibodies has been shown to protect against...
<div><p>HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus ac...
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutr...
Our central hypothesis is that protection against HIV infection will be powerfully influenced by the...
Although IgA is the most abundantly produced immunoglobulin in humans, its role in preventing HIV-1 ...
A major challenge for the development of a highly effective AIDS vaccine is the identification of me...
Simian-human immunodeficiency virus (SHIV) models for human immunodeficiency virus (HIV) infection h...
Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important i...
Although live-attenuated human immunodeficiency virus-1 (HIV) vaccines may never be used clinically,...
AbstractImmune correlates of vaccine protection from HIV-1 infection would provide important milesto...
Non-human primates (NHPs) are the only animal model that are used to evaluate the protection efficac...
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across muc...
Improved vaccine-mediated protection against HIV-1 requires a thorough understanding of the mode of ...
Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but impor...
Improved vaccine-mediated protection against HIV-1 requires a thorough understanding of the mode of ...
ObjectivePassive administration of broadly neutralizing antibodies has been shown to protect against...
<div><p>HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus ac...
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutr...
Our central hypothesis is that protection against HIV infection will be powerfully influenced by the...
Although IgA is the most abundantly produced immunoglobulin in humans, its role in preventing HIV-1 ...
A major challenge for the development of a highly effective AIDS vaccine is the identification of me...
Simian-human immunodeficiency virus (SHIV) models for human immunodeficiency virus (HIV) infection h...
Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important i...
Although live-attenuated human immunodeficiency virus-1 (HIV) vaccines may never be used clinically,...
AbstractImmune correlates of vaccine protection from HIV-1 infection would provide important milesto...